Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron

被引:0
|
作者
Hejun Liu
Chengzi I. Kaku
Ge Song
Meng Yuan
Raiees Andrabi
Dennis R. Burton
Laura M. Walker
Ian A. Wilson
机构
[1] The Scripps Research Institute,Department of Integrative Structural and Computational Biology
[2] Adimab,Department of Immunology and Microbiology
[3] LLC,The Skaggs Institute for Chemical Biology
[4] The Scripps Research Institute,undefined
[5] Ragon Institute of MGH,undefined
[6] MIT and Harvard,undefined
[7] Adagio Therapeutics,undefined
[8] Inc,undefined
[9] The Scripps Research Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Studying the antibody response to SARS-CoV-2 informs on how the human immune system can respond to antigenic variants as well as other SARS-related viruses. Here, we structurally identified a YYDRxG motif encoded by IGHD3-22 in CDR H3 that facilitates antibody targeting to a functionally conserved epitope on the SARS-CoV-2 receptor binding domain. A computational search for a YYDRxG pattern in publicly available sequences uncovered 100 such antibodies, many of which can neutralize SARS-CoV-2 variants and SARS-CoV. Thus, the YYDRxG motif represents a common convergent solution for the human humoral immune system to target sarbecoviruses including the Omicron variant. These findings suggest an epitope-targeting strategy to identify potent and broadly neutralizing antibodies for design of pan-sarbecovirus vaccines and antibody therapeutics.
引用
收藏
相关论文
共 50 条
  • [21] Monoclonal antibodies neutralizing circulating SARS-CoV-2 variants of concern
    Kovacech, Branislav
    Fialova, Lubica
    Filipcik, Peter
    Skrabana, Rostislav
    Zilkova, Monika
    Kovac, Andrej
    Rolkova, Gabriela Paulikova
    Tomkova, Katarina
    Csokova, Natalia Turic
    Markova, Karina
    Skrabanova, Michaela
    Majerova, Petra
    Hanes, Jozef
    Cehlar, Ondrej
    Cente, Martin
    Piestansky, Juraj
    Slavikova, Monika
    Borsova, Kristina
    Cabanova, Viktoria
    Brejova, Bronislava
    Vinar, Tomas
    Nosek, Jozef
    Klempa, Boris
    Eyer, Ludek
    Honig, Vaclav
    Palus, Martin
    Ruzek, Daniel
    Vyhlidalova, Tereza
    Strakova, Petra
    Mrazkova, Blanka
    Zudova, Dagmar
    Koubkova, Gizela
    Novosadova, Vendula
    Prochazka, Jan
    Sedlacek, Radislav
    Zilka, Norbert
    Kontsekova, Eva
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 53 - 54
  • [22] Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike
    Changrob, Siriruk
    Fu, Yanbin
    Guthmiller, Jenna J.
    Halfmann, Peter J.
    Li, Lei
    Stamper, Christopher T.
    Dugan, Haley L.
    Accola, Molly
    Rehrauer, William
    Zheng, Nai-Ying
    Huang, Min
    Wang, Jiaolong
    Erickson, Steven A.
    Utset, Henry A.
    Graves, Hortencia M.
    Amanat, Fatima
    Sather, D. Noah
    Krammer, Florian
    Kawaoka, Yoshihiro
    Wilson, Patrick C.
    MBIO, 2021, 12 (06):
  • [23] PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron
    Su, Jingyi
    Zheng, Jing
    Huang, Wei
    Zhang, Yali
    Lv, Cairui
    Zhang, Baoding
    Jiang, Lina
    Cheng, Tong
    Yuan, Quan
    Xia, Ningshao
    Zhang, Jianming
    Li, Li
    Li, Li
    Deng, Xianming
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [24] Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
    Santos da Silva, Eveline
    Servais, Jean-Yves
    Kohnen, Michel
    Arendt, Vic
    Staub, Therese
    Kruger, Rejko
    Fagherazzi, Guy
    Wilmes, Paul
    Hubschen, Judith M.
    Ollert, Markus
    Perez-Bercoff, Danielle
    Seguin-Devaux, Carole
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [25] Is Omicron the last SARS-CoV-2 Variant of Concern?
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (03) : 336 - 338
  • [26] Omicron: A SARS-CoV-2 variant of real concern
    Gattinger, Pia
    Tulaeva, Inna
    Borochova, Kristina
    Kratzer, Bernhard
    Trapin, Doris
    Kropfmuller, Anna
    Pickl, Winfried F.
    Valenta, Rudolf
    ALLERGY, 2022, 77 (05) : 1616 - 1620
  • [27] Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
    Yu, Jingyou
    Collier, Ai-ris Y.
    Rowe, Marjorie
    Mardas, Fatima
    Ventura, John D.
    Wan, Huahua
    Miller, Jessica
    Powers, Olivia
    Chung, Benjamin
    Siamatu, Mazuba
    Hachmann, Nicole P.
    Surve, Nehalee
    Nampanya, Felix
    Chandrashekar, Abishek
    Barouch, Dan H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (16):
  • [28] Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies
    Schulz, Sebastian R.
    Hoffmann, Markus
    Roth, Edith
    Pracht, Katharina
    Burnett, Deborah L.
    Mazigi, Ohan
    Schuh, Wolfgang
    Manger, Bernhard
    Mielenz, Dirk
    Goodnow, Christopher C.
    Christ, Daniel
    Poehlmann, Stefan
    Jaeck, Hans-Martin
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 (06) : 970 - 977
  • [29] Stability of SARS-CoV-2 variants of concern (Delta and Omicron) on surfaces at room temperature
    Pottage, Thomas
    Onianwa, Okechukwu
    Atkinson, Barry
    Spencer, Antony
    Bennett, Allan M.
    VIROLOGY, 2023, 583 : 27 - 28
  • [30] Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants
    Rodriguez, Lauren
    Zamora, J. Lizbeth Reyes
    Han, Dong
    Moshiri, Jasmine
    Peinovich, Nadine
    Martinez, Clarissa
    Ho, Pui Yan
    Li, Jiani
    Aeschbacher, Thomas
    Martin, Ross
    Pekosz, Andrew
    Bilello, John P.
    Perry, Jason K.
    Hedskog, Charlotte
    VIRUSES-BASEL, 2025, 17 (02):